Improved Outcomes For Children With Cancer Through Improved Target Identification And Drug Discovery: Neuroblastoma As A Model
Funder
National Health and Medical Research Council
Funding Amount
$6,394,247.00
Summary
The majority of children with neuroblastoma still die of their disease, and survivors have serious side-effects of cancer treatment. We aim to discover better therapies for children with this cancer, conducting clinical trials using existing and new drugs in novel combinations. We will also investigate novel ways of targeting neuroblastoma cells, and study possible prevention strategies for this and other embryonal cancers. This work will have application in other childhood and adult cancers.
Central to improving the management of patients with cancer is an understanding of the molecular drivers of cancer. Based on our fundamental discoveries about the role of cell growth and perturbed cell signalling as drivers of cancer we will use the integration of molecular and imaging biomarkers with targeted therapies to translate this knowledge into better outcomes for cancer patients with defined molecular drivers of their cancer.